EMBARGOED: Study reveals activity of navtemadlin in glioblastoma, points to possible treatment improvements
2025-02-19
(Press-News.org)
Study Title: Window of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma
Publication: Science Translational Medicine
Dana-Farber Cancer Institute authors: Veronica Rendo, PhD, Eudocia Q. Lee, MD, MPH, Veronica Rendo, PhD Patrick Y. Wen, MD, Keith L. Ligon, MD, PhD, Rameen Beroukhim, MD, PhD
Summary: Clinical research by Dana-Farber scientists suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could increase efficacy. Navtemadlin is an MDM2 inhibitor that can help to kill cancer cells by boosting the activity of p53, a protein that controls cell growth and induces cell death in response to DNA damage. In lab experiments, the researchers found that navtemadlin was one of the best drugs at killing glioblastoma cells with intact, non-mutant p53.
In this clinical trial, patients received navtemadlin, followed by surgery to remove tumor tissue, enabling the researchers to see how well the drug penetrated the tumor and understand its effects on cancer cells. They found that navtemadlin reached effective concentrations in the tumor and activated the p53 pathway, but the tumors eventually relapsed. The team then used tissue samples from three relapses and other patients to create patient-derived tumor models. They tested a range of navtemadlin dosing and combinations on these tumor models and found that combining navtemadlin with other DNA-damaging chemotherapy, such as temozolomide, could increase the rates at which cancer cells die.
Significance: Glioblastoma is the most aggressive and most common malignant brain cancer in adults. It is currently treated with surgery, followed by radiation and chemotherapy. Prognosis is poor even with treatment. A challenge in conducting clinical trials in brain cancer is that it can be difficult to detect the cellular effects of new agents, as investigators are often limited to using imaging data and patient symptoms. This trial of navtemadlin sampled tumors on treatment, enabling the investigators to understand its effects in detail and conduct additional studies to optimize treatment strategies. This study suggests that a combination therapy strategy has the potential to increases the efficacy of navtemadlin and stave off resistance.
Funding: National Institutes of Health, and the Massachusetts Life Sciences Center.
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-02-19
Boston - Kimberly Stegmaier, MD, was named Chair of Pediatric Oncology at Dana-Farber Cancer Institute and Associate Chief of the Division of Hematology/Oncology at Boston Children’s Hospital, in an announcement made today. Her appointment is effective April 1, 2025.
Stegmaier, a Dana-Farber, Boston Children’s Hospital, and Harvard Medical School faculty member since 2002, Stegmaier is currently Vice Chair for Pediatric Oncology Research at Dana-Farber, Co-Director of the Pediatric Hematologic Malignancy Program at Dana-Farber and Boston Children’s Hospital, Co-Leader for the Dana-Farber/Harvard Cancer Center Leukemia Program, and a Professor ...
2025-02-19
NEW YORK – The Human Immunome Project (HIP) and Michelson Medical Research Foundation (MMRF) have awarded Dr. Omar Abudayyeh (Brigham and Women’s Hospital; Harvard Medical School), Dr. Caleb Lareau (Memorial Sloan Kettering Cancer Center), and Dr. Yuzhong Liu (Scripps Research) the 2024 Michelson Prizes: Next Generation Grants.
The $150,000 research grants are awarded annually to support early-career scientists advancing human immunology, vaccine discovery, and immunotherapy research for major global diseases.
“Investing in bold, early-career scientists fuels the high-risk, high-reward ideas ...
2025-02-19
After a year of weather extremes that brought everything from deadly floods to bitter cold, experts at East Tennessee State University have released a detailed analysis of the region’s 2024 weather patterns.
Their findings highlight both record-breaking temperatures and catastrophic storms – underscoring the growing need for preparedness as communities face unpredictable conditions.
The report, published by Tennessee’s Climate Office housed at ETSU, details how Southern Appalachia endured scorching heat and devastating floods, including the tragic September storm linked to ...
2025-02-19
Humans have appreciated the beauty of flowers for centuries. Yet, flowers aren’t just aesthetically pleasing. They also play a crucial role in plant reproduction. In all plants, a well-studied gene with a curious name, Unusual Floral Organs (UFO), orchestrates the flowering process. UFO expression hinges on another complex process called cis-regulation. And this one has remained a “black box” of plant biology research for years.
Now, using CRISPR gene editing, Cold ...
2025-02-19
PHILADELPHIA – Cancer patients spend a lot of time on their care. Meeting with doctors and other members of their health care team, getting labs and other tests, picking up prescriptions, and undergoing treatment all takes time. So does getting to and from each appointment, sitting in the waiting room between each appointment, and so on.
In recent years, cancer researchers have worked to quantify the level of “time toxicity” or time spent commuting to, waiting for, and receiving cancer treatment. Now, for the first time, a pilot study has shown it’s possible to use digital technology to safely ...
2025-02-19
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.
The study, published Jan. 30 in the Journal of Antimicrobial Chemotherapy, adds to growing evidence that lenacapavir may be a powerful new tool in the global anti-HIV drug arsenal. Approximately, 1.5 million people are living with HIV in Uganda.
“Our data shows that only 1.6% of the individuals studied are living with HIV ...
2025-02-19
There are currently around 275,000 glaciers worldwide, in which huge quantities of fresh water are stored. But this reservoir is increasingly shrinking. Since the turn of the millennium, glaciers around the world – i.e. ice masses on land excluding the Greenland and Antarctic ice sheets – have lost around 273 billion tonnes of ice per year. This corresponds to about five and a half times the volume of Lake Constance. Overall, the world’s glaciers have lost around five per cent of their total volume since the year 2000. This is the conclusion reached by an international research team of which Tobias Bolch from the Institute of Geodesy ...
2025-02-19
February 19, 2025-- Breast cancer incidence trends in U.S. women under 40 vary by geography and supports incorporating location information with established risk factors into risk prediction, improving the ability to identify groups of younger women at higher risk for early-onset breast cancer, according to a new study at Columbia University Mailman School of Public Health. This study comprehensively examined trends across different states, regions, metropolitan versus non-metropolitan areas and by racial and ethnic groups. It also is one of the first to incorporate ...
2025-02-19
A three-year effort to encourage California prosecutors to reconsider the sentences given to some people in state prison has resulted in a modest number of people being resentenced, but improvements are needed to speed review of more cases, according to a new RAND report.
During the project involving nine counties, more than 1,100 cases received an initial review. After comprehensive reviews by county district attorneys for the suitability for resentencing, 227 individuals eventually received new sentences and 174 of those offenders had been released ...
2025-02-19
Propane dehydrogenation (PDH), as an efficient catalytic production process to obtain propylene, has developed rapidly in recent years. Previous studies have shown that zirconia exhibited excellent performance in the PDH, with the coordination-unsaturated zirconium (Zrcus) around the oxygen vacancy being the active site in the reaction. However, the critical role of oxygen vacancy is still remaining elusive, and lacked a rationale to establish a relation between structure and performance. Moreover, the strong binding of propene and hydrogen molecules shadowed ...
LAST 30 PRESS RELEASES:
[Press-News.org] EMBARGOED: Study reveals activity of navtemadlin in glioblastoma, points to possible treatment improvements
